Woodline Partners LP Acquires 90,940 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Woodline Partners LP lifted its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,139,593 shares of the company's stock after acquiring an additional 90,940 shares during the quarter. Woodline Partners LP owned approximately 7.75% of Zevra Therapeutics worth $34,524,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ZVRA. BNP Paribas Financial Markets bought a new stake in Zevra Therapeutics in the 4th quarter worth about $53,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Zevra Therapeutics in the fourth quarter valued at approximately $94,000. Squarepoint Ops LLC increased its position in shares of Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after acquiring an additional 4,384 shares during the last quarter. ProShare Advisors LLC bought a new stake in Zevra Therapeutics during the fourth quarter worth $145,000. Finally, Invesco Ltd. boosted its position in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after purchasing an additional 3,007 shares during the last quarter. Institutional investors own 35.03% of the company's stock.

Wall Street Analyst Weigh In

ZVRA has been the subject of several research analyst reports. Guggenheim raised their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group increased their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $22.29.

Insider Activity

In other news, Director John B. Bode bought 10,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were acquired at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now directly owns 40,000 shares of the company's stock, valued at $318,400. This trade represents a 33.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by company insiders.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock traded up $0.08 during mid-day trading on Friday, reaching $8.65. The company's stock had a trading volume of 375,522 shares, compared to its average volume of 643,411. The company has a market capitalization of $472.98 million, a P/E ratio of -4.39 and a beta of 1.87. The firm's fifty day moving average price is $7.59 and its two-hundred day moving average price is $8.09. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same period in the previous year, the company posted ($0.40) EPS. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.